Key Stats for Altria Stock
- 52-Week Range: $55 to $75
- Current Price: $72
- Street Mean Target: $70
- Street High Target: $82
- Analyst Consensus: 4 Buy, 7 Hold, 1 Underperform, 1 Sell
- TIKR Model Target (Dec. 2030): $33
Altria Beats EPS by 6% and Hits a 9-Year Price High as Marlboro Defends Premium
Altria Group (MO), the Richmond-based maker of Marlboro cigarettes and the on! nicotine pouch, jumped as much as 8.3% intraday on April 30 after reporting first-quarter results that beat on every line that mattered.
The company posted revenue of $4.76 billion, ahead of the $4.58 billion analysts had expected.
Adjusted EPS came in at $1.32, 6% above the $1.25 consensus, representing 7.3% growth over the same quarter a year earlier.
Shares reached $73.85 intraday, their highest level since December 2017.
The beat was not a cost story.
Smokeable segment adjusted operating company income grew 6.3%, with margins expanding to 65.1%, driven by net price realization of 6.3%.
Domestic cigarette volumes declined 2.4% on a reported basis in Q1, marking the fourth consecutive quarter of sequential year-over-year improvement, which management attributed primarily to moderation in cross-category movement from cigarettes to illicit flavored e-vapor products.
Marlboro expanded its share of the premium segment to 59.5%, up 0.1 percentage points versus the prior year and 0.2 points sequentially.
On! PLUS, the Altria’s next-generation nicotine pouch and the first product authorized under the FDA’s pilot program for streamlined reviews, shipped nationally starting in March and was available in approximately 100,000 stores by quarter-end, representing roughly 85% of nicotine pouch category volume.
Total on! portfolio shipment volume grew nearly 18% to over 46 million cans.
Outgoing CEO Billy Gifford, who stepped down in mid-May after more than 20 years with the company, noted in Q1 2026 earnings call that the illicit e-vapor market appeared to be moderating: “After several years of rapid growth, we began to see signs of moderation in the back half of 2025.”
The company reaffirmed full-year 2026 adjusted EPS guidance in a range of $5.56 to $5.72, representing growth of approximately 3% to 6% from the $5.42 base in 2025, and indicated growth would now be more evenly split between the first and second halves.
Meanwhile, six Democratic senators sent public letters to Altria and Reynolds American on June 4 demanding details on political donations and lobbying related to the FDA’s new enforcement discretion policy, which allows manufacturers to sell vapes and nicotine pouches without the standard premarket authorization. Altria said it is reviewing the implications for its product strategy and will continue to compete within the FDA-regulated marketplace.
What Wall Street Is Paying $70 for After Altria Stock Beats EPS and Hits a 9-Year High
At 13 analysts covering the stock as of June 5, the consensus on Altria stock is cautious. Four rate it Buy, seven Hold, one Underperform, and one Sell. The Street mean target of $70 sits slightly below the current price near $72, suggesting the majority of analysts view the Q1-driven rally as having closed most of the near-term gap.
The strongest single data point from Q1 was adjusted EPS of $1.32, which topped the $1.25 consensus by $0.07. On a forward basis, analysts estimate $1.49 for Q2 2026 and $1.50 for Q3, before a seasonal step-down to around $1.37 in Q4.
Meanwhile, Altria stock’s revenue of $4.76 billion in Q1 grew approximately 5% year over year and outpaced the $4.58 billion estimate by a meaningful margin. The forward consensus expects around $5.34 billion in Q2 and roughly $5.32 billion in Q3, suggesting full-year revenues stay roughly flat year over year.
At the current price, Altria stock appears to be fairly valued relative to near-term Street consensus, with the mean sitting fractionally below the share price and the buy-hold-sell split implying limited directional conviction.
MO Stock Earns More Per Quarter Than PM — but Philip Morris Is Growing That Gap
Altria stock’s nearest earnings peer is not in the same race.
Philip Morris International (PM) posted normalized EPS of $1.83 in Q1 2026, against Altria stock’s $1.32 for the same period, a gap of $0.51 per share in a single quarter that reflects two fundamentally different revenue bases: Altria is a domestic tobacco company; Philip Morris operates globally and owns Zyn, the nicotine pouch brand that has been taking share from Altria’s on! in the U.S.
The forward consensus widens that gap rather than closes it, with Philip Morris expected to reach $2.43 in Q3 2026 against Altria stock’s estimated $1.50 for the same period.
What the chart also shows is that Altria stock’s quarterly EPS has been range-bound between $1.30 and $1.45 for the past year, while Philip Morris has been climbing, moving from $1.86 in Q2 2025 to an estimated $2.43 by Q3 2026 against Altria’s $1.50.
The comparison does not make Altria stock unattractive; it defines the question precisely: Altria generates reliable, high-margin domestic cash flow with a meaningful dividend yield, while Philip Morris is compounding EPS at a faster rate from a higher base, and the market prices that difference into both stocks.
Is Altria Stock Undervalued in 2026? TIKR’s $86 Target and the On! PLUS Variable
TIKR’s base case values Altria Group at approximately $86 by December 2030, implying around 19% total return from the current price near $72, or roughly 4% annualized over the next 4.6 years.
If cigarette volume declines continue moderating toward the low single-digit range and on! PLUS secures additional flavor authorizations currently under FDA review, TIKR’s high case projects a stock price near $129 at the end of the full forecast horizon, representing around 79% total return and roughly 7% annualized.
If volumes re-accelerate downward and the FDA moves slowly on new pouch approvals, the low case still projects roughly $93, with around 28% total return and around 3% annualized, anchored by the durability of Marlboro pricing and the oral tobacco segment’s over $400 million in quarterly adjusted operating income.
Across all three scenarios, Altria stock produces positive total returns. The Street’s near-term caution is grounded in genuine macro and volume uncertainty. But a company generating 6.3% net price realization in its core business, growing nicotine pouch shipments by nearly 18% in a single quarter, and reaffirming earnings guidance after a meaningful beat is not simply a cigarette company in managed decline. Altria stock is modestly undervalued when the model’s full horizon and dividend yield are weighed against the current price.
Is Altria stock a buy right now?
TIKR’s base case targets approximately $86 for Altria stock by December 2030, implying around 19% total return from the current price.
The near-term Street consensus is cautious, with a mean target of $70 against a current price near $72.
The investment case depends on whether on! PLUS flavor authorizations move forward and whether cigarette volume declines stay in the low single-digit range.
What do analysts say about Altria stock?
As of June 5, 2026, the analyst breakdown is 4 Buy, 7 Hold, 1 Underperform, and 1 Sell, with a Street mean target of $70 and a high target of $82.
Analysts acknowledge the Q1 beat, with adjusted EPS of $1.32 topping consensus by $0.07, but remain cautious on sustained volume trends and macroeconomic pressure on lower-income consumers.
Should You Invest in Altria Group, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Altria Group, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Altria Group, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze MO stock on TIKR for Free →
